New eye drug shows promise in battle against blinding disease
NCT ID NCT07389577
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new medicine called JL14002 against a standard treatment (ranibizumab) for wet age-related macular degeneration, a leading cause of vision loss. 443 adults aged 50-80 with active disease received injections into the eye. The main goal was to see if JL14002 improved vision as well as the standard drug over 12 weeks, with follow-up for a year. The approach aims to control the disease and preserve sight.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WET AGE RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
Beijing, China